Risk stratification in clinically localized prostate cancer.

Area of Science:

• Urology
• Oncology
• Medical Statistics

Background:

• Clinical outcomes for localized prostate cancer are highly variable.
• Large-scale data analyses have improved risk assessment for localized prostate cancer.
• Key prognostic factors include biopsy Gleason score, clinical T stage, and serum prostate-specific antigen (PSA).

Purpose of the Study:

• To review the established parameters for risk stratification in localized prostate cancer.
• To discuss the utility and limitations of predictive tools like Partin Tables and nomograms.
• To highlight the role of these tools in comparing treatment modalities and designing clinical trials.

Main Methods:

• Review of existing literature and clinical data analyses.
• Examination of predictive models such as Partin Tables and nomograms.
• Analysis of the independent predictive value of various prognostic factors.

Main Results:

• Biopsy Gleason score, clinical T stage, and serum PSA are consistently correlated with clinical outcomes.
• Partin Tables and nomograms incorporating these factors aid in estimating metastasis risk and predicting recurrence.
• Additional factors have not consistently improved prediction accuracy beyond these three principal parameters.

Conclusions:

• Serum PSA, T-stage, and Gleason score are the primary parameters for risk stratification in localized prostate cancer.
• Predictive tools based on these factors are valuable for individual prognostication and comparing treatment outcomes.
• The greatest benefit of risk stratification lies in comparing patient series and informing clinical trial design.